FDA Clears Eloxx IND for Exaluren in ADPKD; First Dosing Set for 3Q 2027
ELOX filed a Product Development and Regulatory on light trading volume (0.3× avg).
Summary
The FDA cleared Eloxx's IND for exaluren in nonsense-mutation ADPKD, letting the company move into the clinic with a 60-patient randomized study. First dosing is targeted for 3Q 2027, with topline data in 1H 2029 — a long runway before any readout. For a micro-cap biotech that posted an $8.3 million first-half loss and ended June with $62 million, this is a genuine pipeline expansion beyond its core programs, but the cash burn has to carry the company for roughly two and a half years before the first patient is even dosed. The 2029 data timeline means no near-term clinical catalyst; the next hard checkpoints are quarterly cash burn and any financing needed to fund the trial.
At the time of this announcement, ELOX was trading at $13.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53M. The 52-week trading range was $0.02 to $23.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.